Journal article
A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice
T Donnison, J McGregor, S Chinnakannan, C Hutchings, RJ Center, P Poumbourios, P Klenerman, HE Drummer, E Barnes
Hepatology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022
DOI: 10.1002/hep.32470
Abstract
Background and Aims: A prophylactic vaccine targeting multiple HCV genotypes (gt) is urgently required to meet World Health Organization elimination targets. Neutralizing antibodies (nAbs) and CD4+ and CD8+ T cells are associated with spontaneous clearance of HCV, and each may contribute to protective immunity. However, current vaccine candidates generate either nAbs or T cells targeting genetically variable epitopes and have failed to show efficacy in human trials. We have previously shown that a simian adenovirus vector (ChAdOx1) encoding conserved sequences across gt1-6 (ChAd-Gt1-6), and separately gt-1a E2 protein with variable regions deleted (E2Δ123HMW), generates pan-genotypic T cells..
View full abstractGrants
Awarded by NIHR Oxford Biomedical Research Centre
Funding Acknowledgements
Supported by the National Health and Medical Research Council (project grant: 1146082). H.E. D. was the recipient of a National Health and Medical Research Council Research fellowship (1041897). The Burnet Institute gratefully acknowledges support from the Victorian Operational Infrastructure Support program. E.B. was funded by the Medical Research Council UK (MR/K010239/1), the Oxford NIHR Biomedical Research Centre, and the Oxford Martin School (HCMIGGS1) and is an NIHR Senior Investigator. T. D. was a recipient of a Nuffield Department of Medicine (NDM; 1514261) DPhil Prize Studentship, a Medical Research Council (MRC) Supplementary Fund, and an MRC Confidence in Concept Fund (MC_PC_17174). S.C. was funded by the MRC (MR/K010239/1).